Genotypic resistance mutations to antiretroviral drugs in treatment-naive HIV/AIDS patients living in Liaoning Province, China: Baseline prevalence and subtype-specific difference

AIDS Research and Human Retroviruses

Volumn 23, Issue 3, 2007, Pages 357-364

  Han, Xiaoxu ^a   Zhang, Min ^a   Dai, Di ^a   Wang, Yanan ^a   Zhang, Zining ^a   Liu, Jing ^a   Geng, Wenqing ^a   Jiang, Yongjun ^a   Takebe, Yutaka ^b   Shang, Hong ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; CHINA; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS GENE; VIRUS MUTATION;

ADULT; CHINA; DRUG RESISTANCE, MULTIPLE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; POINT MUTATION; POLYMORPHISM, GENETIC; PREVALENCE; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 34247247619     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.0094     Document Type: Article

References (22)

1. Hirsch MS, Conway B, D'Aquila RT, et al.: Antiretroviral drug resistance testing in adults with HIV infection. JAMA 1998;279: 1984-1991
2. Vandamme AM, Van Laethem K, et al.: Managing resistance to anti-HIV drugs: An important consideration for effective disease management. Drugs 1999;57:337-361.
3. Metzner KJ, Rauch P, Walter H, et al.: Detection of minor populations of drug resistant HIV-1 in acute seroconverters. Antiviral Ther 2005;10:S123.
4. Hirsch MS, Brun-Vezinet F, D'aquila RT, et al.: Antiretroviral drug resistance testing in adults with HIV infection. JAMA 2000;283: 2417-2426.
5. Feinberg M: Hidden dangers of incompletely suppressive antiretroviral therapy. Lancet 1997;349:1408-1409
6. Finzi D, Hermankova M, Poerson T, et al.: Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-1300.
7. Rafeal RD, Carlos B, and Vincent S, et al.: Introduvtion of HIV drug-resistance testing in clinical practice. AIDS 1999;13:1007-1014
8. Markus B and Anders S: Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients. AIDS 1998;12:2369-2375.
9. Hammond J, Calef C, Larder B, et al.: Mutations in retroviral genes associated with drug resistance. In: Human Retroviruses and AIDS, Part III. Los Alamos National Laboratory, Los Alamos, NM, 1998 pp. 36-79.
10. Erickson, JW, Gulnik SV, and Markowitz M: Protease inhibitors: Resistance, cross-resistance, fitness and the choice of initial and salvage therapies. AIDS 1999;13:S189-S204.
11. Shao YM, Su L, Sun XH, et al.: Molecular epidemiology of HIV infection in China. XII International Conference on AIDS, June 1998, Geneva.
12. Han XX, Lu CM, Zhou LP, et al.: Subtype and sequence analysis of HIV-1 strains in Liaoning province. Zhong guo gong gong wei sheng 2003;19:1312-1313 (in Chinese).
13. Brideiro PA, Brindeiro RM, Mortensen C, et al.: Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy. J Clin Microbiol 2002;40:4512-4519.
14. Caride E, Hertogs K, Larder B, et al.: Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virus type 1 found in Brazilian patients failing HAART. Virus Genes 2001; 23:193-202.
15. Sax PE, Islam R, Walensky RP, et al.: Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 2005;41:1324-1325.
16. Novak RM, Chen L, MacArthur RD, et al.: Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: Implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis 2005;40:468-474.
17. Brideiro PA, Brindeiro RM, Mortensen C, et al.: Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy. J Clin Microbiol 2002;40:4512-4519.
18. Pires IL, Soares MA, and Speranza FA: Prevalence of human immunodeficiency virus drug resistance mutations and subtypes in drug-naive, infected individuals in the Army Health Service of Rio de Janeiro, Brazil. J Clin Microbiol 2004;42:426-430.
19. Laeyendecker O, Zhang GW, Quinn TC, et al.: Molecular epidemiology of HIV-1 subtypes in southern China. J Acquir Immune Defic Syndr 2005;38:356-362.
20. Holguin A, Ramirez de Arellano E, et al.: Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes. AIDS Rev 2006;8:98-107.
21. Holguin A, Sune C, Hamy F, et al.: Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure. J Clin Virol 2006;36: 264-271.
22. Li JY, Li HP, Li L, Li H, et al.: Prevalence and evolution of drug resistance HIV-1 variants in Henan, China. Cell Res 2005;15:843-849.